Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
896.10Today’s High
948.0052W low
213.2052W High
995.00Open Price
938.00Prev. Close
545.4000Volume
1323535.00Value
1202563901.00Fundamentals
Market Cap
13938.00
Price to Earnings
-30.10
Price to Book Value
3.80
Dividend Yield
0.00
PE to Growth
-1.70
Op Revenue TTM
2798.00
Net Profit TTM
-463.00
Cash From Operating Activity
219.00
Return on Equity %
-13.78
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
44.2
Week
34.9
Month
46.8
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
917.55
PIVOT
First Resistance
939.00
Second Resistance
969.40
Third Resistance
990.85
First Support
887.15
Second Support
865.70
Third Support
835.30
Relative Strength Index
85.57
Money Flow Index
93.79
MACD
86.49
MACD Signal
51.76
Average True Range
48.21
Average Directional Index
38.29
Rate of Change (21)
74.7
Rate of Change (125)
83.8
Commodity Channel Index
155.1
Williams %R
-19.5
BETA
1 Month
0.68
3 Month
1.05
1 Year
1.18
3 Year
0.69
PRICE CHANGE ANALYSIS
↑ 32.33%
1 Week
Low
High
730.5
995
↑ 74.7%
1 Month
Low
High
524.1
995
↑ 55.4%
3 Months
Low
High
490.15
995
↑ 86.65%
6 Months
Low
High
402.65
995
↑ 274.37%
1 Year
Low
High
213.25
995
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 379.00 | 293.00 | 266.00 | 257.00 | 320.00 | 300.00 | 287.00 | 290.00 | 496.00 | 311.62 | 314.63 | |
| Operating Expenses Qtr | 401.00 | 263.00 | 270.00 | 256.00 | 321.00 | 256.00 | 247.00 | 236.00 | 288.00 | 293.53 | 300.97 | |
| Operating Profit Qtr | -46.00 | 25.00 | -10.00 | -5.00 | -30.00 | 26.00 | 11.00 | 5.00 | 186.00 | 15.08 | 9.47 | |
| EBIDT Qtr Cr | -22.00 | 30.00 | -4.00 | -13.00 | -186.00 | 44.00 | -10.00 | 54.00 | 208.00 | 18.09 | 13.66 | |
| Depreciation Qtr | 45.00 | 43.00 | 44.00 | 44.00 | 45.00 | 47.00 | 47.00 | 47.00 | 43.00 | 42.86 | 43.16 | |
| Net Profit Qtr | -126.00 | -74.00 | -107.00 | -115.00 | -299.00 | -55.00 | -75.00 | -37.00 | 40.00 | -67.12 | -63.70 | |
| Basic EPS Qtr | -8.71 | -5.14 | -7.39 | -8.01 | -20.80 | -3.81 | -5.17 | -2.62 | 3.24 | -6.06 | -5.75 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 1195.00 | 1139.00 | 1410.00 | 1027.99 | 933.08 | |
| Operating Expenses Annual Cr | 1190.00 | 1002.00 | 1150.00 | 1124.96 | 1023.20 | |
| Operating Profit Annual | -36.00 | 70.00 | 222.00 | -137.70 | -133.14 | |
| Operating Profit Margin Annual % | -3.01 | 6.15 | 15.74 | -13.40 | -14.27 | |
| Total Expenses Annual Cr | 1603.00 | 1417.00 | 1594.00 | 1509.28 | 1416.76 | |
| EBIDT Annual Cr | 5.00 | 137.00 | 260.00 | -96.97 | -90.12 | |
| EBIDT Annual margin % | 0.42 | 12.03 | 18.44 | -9.43 | -9.66 | |
| Depreciation | 176.00 | 186.00 | 171.00 | 184.08 | 173.39 | |
| PAT Before ExtraOrdinary Items Annual Cr | -422.00 | -466.00 | -140.00 | 1078.28 | -325.68 | |
| Net Profit Annual | -422.00 | -466.00 | -140.00 | 593.29 | -231.12 | |
| Basic EPS Annual | -29.27 | -32.40 | -11.62 | 53.57 | -20.88 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 1796.00 | 1753.00 | 2212.00 | 1605.76 | 994.62 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 1184.00 | 353.00 | 537.00 | 686.35 | 1459.64 | |
| Total Current Liabilities Annual Cr | 1888.00 | 2626.00 | 3049.00 | 2602.79 | 2305.25 | |
| Total Capital Plus Liabilities Annual Cr | 4868.00 | 4732.00 | 5798.00 | 4894.90 | 4759.51 | |
| Fixed Assets Annual | 2282.00 | 2448.00 | 2653.00 | 2399.36 | 2349.64 | |
| Total Non Current Assets Annual | 3089.00 | 3257.00 | 3410.00 | 3055.93 | 3152.96 | |
| Total Current Assets Annual | 1779.00 | 1475.00 | 2388.00 | 1838.97 | 1606.55 | |
| Total Assets Annual | 4868.00 | 4732.00 | 5798.00 | 4894.90 | 4759.51 | |
| Contingent Liabilities plus Commitments Annual Cr | 935.46 | 898.26 | 25.00 | 577.94 | 1511.84 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 188.00 | 71.00 | -93.00 | -563.97 | 221.51 | |
| Cash from Investing Activity Annual | -75.00 | -3.00 | -244.00 | 1014.34 | -16.15 | |
| Cash from Financing Annual Activity | 346.00 | -236.00 | 430.00 | -479.85 | -273.97 | |
| Net Cash Flow Annual | 459.00 | -168.00 | 93.00 | -29.48 | -68.61 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 116.62 | 121.74 | 153.61 | 144.95 | 89.82 | |
| ROE Annual % | -23.49 | -26.58 | -6.32 | 36.94 | -23.23 | |
| ROCE Annual % | -5.73 | -2.32 | 3.23 | -12.26 | -10.73 | |
| Total Debt to Total Equity Annual | 1.00 | 0.92 | 0.72 | 0.83 | 1.41 | |
| EBDIT Annual Margin % | 0.43 | 12.77 | 18.95 | -9.82 | -10.12 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 754.00 | 709.00 | 777.00 | 658.00 | 710.00 | 701.00 | 736.00 | 652.00 | 669.00 | 855.94 | 867.20 | |
| Operating Expenses Qtr | 803.00 | 664.00 | 681.00 | 628.00 | 675.00 | 654.00 | 636.00 | 611.00 | 688.00 | 742.44 | 766.17 | |
| Operating Profit Qtr | -103.00 | 37.00 | 72.00 | 16.00 | 3.00 | 45.00 | 43.00 | -16.00 | -33.00 | 111.45 | 95.83 | |
| EBIDT Qtr Cr | -49.00 | 45.00 | 96.00 | 16.00 | -61.00 | 44.00 | -95.00 | 41.00 | -202.00 | 113.50 | 101.03 | |
| Depreciation Qtr | 58.00 | 55.00 | 55.00 | 55.00 | 56.00 | 66.00 | 65.00 | 64.00 | 59.00 | 61.98 | 61.21 | |
| Net Profit Qtr | -169.00 | -83.00 | -77.00 | -134.00 | -208.00 | -96.00 | -189.00 | -67.00 | -258.00 | -6.78 | 33.53 | |
| Basic EPS Qtr | -11.64 | -5.75 | -5.37 | -9.28 | -14.37 | -6.62 | -13.15 | -4.64 | -21.20 | -0.61 | 3.03 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 2881.00 | 2773.00 | 3250.00 | 2840.57 | 2882.80 | |
| Operating Expenses Annual Cr | 2759.00 | 2550.00 | 2932.00 | 2771.33 | 2724.96 | |
| Operating Profit Annual | 39.00 | 101.00 | 298.00 | -63.03 | 119.03 | |
| Operating Profit Margin Annual % | 1.35 | 3.64 | 9.17 | -2.22 | 4.13 | |
| Total Expenses Annual Cr | 3287.00 | 3103.00 | 3478.00 | 3266.43 | 3224.84 | |
| EBIDT Annual Cr | 122.00 | 223.00 | 318.00 | 69.24 | 157.84 | |
| EBIDT Annual margin % | 4.23 | 8.04 | 9.78 | 2.44 | 5.48 | |
| Depreciation | 223.00 | 251.00 | 247.00 | 246.02 | 224.14 | |
| PAT Before ExtraOrdinary Items Annual Cr | -472.00 | -621.00 | -279.00 | 1173.59 | -137.95 | |
| Net Profit Annual | -463.00 | -559.00 | -244.00 | 686.06 | -69.22 | |
| Basic EPS Annual | -32.05 | -38.79 | -20.24 | 61.68 | -6.25 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 3359.00 | 3354.00 | 3849.00 | 3376.76 | 2671.67 | |
| Minority Interest Liability Annual Cr | 303.00 | 308.00 | 353.00 | 383.49 | 385.79 | |
| Total Non Current Liabilities Annual Cr | 1196.00 | 586.00 | 834.00 | 894.22 | 1624.27 | |
| Total Current Liabilities Annual Cr | 2791.00 | 3435.00 | 3207.00 | 3118.22 | 3497.18 | |
| Total Capital Plus Liabilities Annual Cr | 7649.00 | 7683.00 | 8243.00 | 7772.69 | 8178.91 | |
| Fixed Assets Annual | 3650.00 | 3636.00 | 3913.00 | 3818.02 | 4211.63 | |
| Total Non Current Assets Annual | 5465.00 | 5475.00 | 5654.00 | 5348.31 | 5749.08 | |
| Total Current Assets Annual | 2184.00 | 2208.00 | 2589.00 | 2424.38 | 2429.83 | |
| Total Assets Annual | 7649.00 | 7683.00 | 8243.00 | 7772.69 | 8178.91 | |
| Contingent Liabilities plus Commitments Annual Cr | 995.46 | 881.26 | 868.00 | 567.64 | 641.08 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 219.00 | 153.00 | 413.00 | -287.32 | 648.96 | |
| Cash from Investing Activity Annual | -137.00 | -125.00 | -201.00 | 1470.10 | -155.53 | |
| Cash from Financing Annual Activity | 334.00 | -315.00 | -71.00 | -1170.82 | -679.58 | |
| Net Cash Flow Annual | 416.00 | -287.00 | 141.00 | 11.96 | -186.15 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 237.79 | 254.31 | 291.81 | 339.43 | 276.09 | |
| ROE Annual % | -13.78 | -16.66 | -6.33 | 20.31 | -2.59 | |
| ROCE Annual % | -2.07 | -0.65 | 1.40 | -3.79 | -1.41 | |
| Total Debt to Total Equity Annual | 0.63 | 0.56 | 0.48 | 0.46 | 0.80 | |
| EBDIT Annual Margin % | 4.36 | 8.41 | 9.84 | 2.55 | 5.54 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Icici Prudential Equity & Debt Fund | 1.26 | 78109098 | - | - |
| Rekha Jhunjhunwala | 1.89 | 78109118 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Themisto Trustee Company Private Limited | 42.61 | 78109088 | 62.57 | 0 |
| Pasithee Trustee Company Private Limited | 3.3 | 78109089 | 0 | 0 |
| Ananke Trustee Company Private Limited | 2.57 | 78109090 | 1.37 | 0 |
| Callirhoe Trustee Company Private Limited | 1.73 | 78109091 | 37.59 | 0 |
| Callirhoe Trustee Company Private Limite | 0.61 | 78109092 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| Icici Prudential Equity & Debt Fund | 1.26 | 78109098 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| Rekha Jhunjhunwala | 1.89 | 78109118 |
| HUF | 1.41 | 78109109 |
| LLP | 0.58 | 78109110 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Nov 17, 2016 | 10 | INTERIM | Nov 19, 2016 | Equity Share |
| Aug 04, 2016 | - | FINAL | - | Preference Shares |
| Nov 13, 2014 | 20 | INTERIM | Nov 15, 2014 | Equity Share |
| Feb 17, 2014 | 5 | INTERIM | Feb 19, 2014 | Equity Share |
| Nov 07, 2013 | 5 | INTERIM | Nov 08, 2013 | Equity Share |
| Aug 22, 2013 | 5 | FINAL | - | Equity Share |
| Apr 17, 2008 | 2.5 | FINAL | - | Equity Share |
| Oct 26, 2007 | 8.75 | INTERIM | Oct 29, 2007 | Equity Share |
| Mar 22, 2007 | 5 | FINAL | Mar 23, 2007 | Equity Share |
| Jun 21, 2006 | 5 | FINAL | - | Equity Share |
| Apr 12, 2005 | 5 | FINAL | - | Equity Share |
| Apr 28, 2004 | 3.75 | FINAL | - | Equity Share |
| Jun 03, 2003 | 6.5 | FINAL | - | Equity Share |
| Apr 22, 2002 | - | FINAL | - | Equity Share |
| May 15, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Apr 28, 2004 | 10:5 | - |
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 28, 2024 | Audited Results | - |
| Mar 26, 2024 | Others | Inter alia, to consider and determine the issue price of Equity Shares to be issued pursuant to the Issue, including any discount, not more than 5%, on the floor price. |
| Feb 14, 2024 | Quarterly Results | - |
| Nov 14, 2023 | Quarterly Results | - |
| Aug 14, 2023 | Quarterly Results | - |
| May 26, 2023 | Audited Results & Others | To consider : Raising of funds by various method as may be permitted under applicable law, subject to consent of shareholder at the ensuing Annual General Meeting and such approvals. |
| Feb 13, 2023 | Quarterly Results | - |
| Nov 04, 2022 | Quarterly Results | - |
| Aug 12, 2022 | Quarterly Results | - |
| May 30, 2022 | Audited Results | - |
| Mar 03, 2022 | Rights issue | - |
| Jan 27, 2022 | Quarterly Results | - |
| Jan 06, 2022 | Rights issue of Equity Shares | - |
| Nov 08, 2021 | Quarterly Results | - |
| Jul 22, 2021 | Quarterly Results | - |
| May 27, 2021 | Audited Results & Others | Inter alia, To consider raising of funds by issue of Equity Shares, Global Depository Receipts, American depository receipts, Foreign Currency Convertible Bonds etc. |
| May 21, 2021 | Others | inter-alia, to consider and approve the proposal for raising of funds through issuance of Non-convertible Debentures on private placement basis. |
| Apr 21, 2021 | Others | inter-alia, to consider and approve the proposal for raising of funds through issuance of Non-Convertible Debentures on private placement basis. |
| Jan 29, 2021 | Quarterly Results | - |
| Nov 02, 2020 | Quarterly Results | - |
| Aug 29, 2020 | Quarterly Results | - |
| May 11, 2020 | Audited Results & Others | Inter alia, to approve raising of funds by issue of Equity Shares, ADR/ GDR / FCCB / FCD / PCD or any other method as may be permitted under applicable law. |
| Jan 27, 2020 | Quarterly Results | - |
| Nov 07, 2019 | Quarterly Results | - |
| Aug 14, 2019 | Quarterly Results | - |
| May 06, 2019 | Audited Results & Others | Dividend on Preference shares |
| Mar 19, 2019 | Capital Raising Committee Meeting | to consider and approve alteration/ extension of the date of redemption of 160,000,000 0.01% Non-Convertible Cumulative Preference Shares (Preference Shares) of face value of Rs. 51- each. |
| Jan 28, 2019 | Quarterly Results | - |
| Nov 10, 2018 | Quarterly Results | - |
| Aug 04, 2018 | Quarterly Results | - |
| May 04, 2018 | Audited Results & Divi. on Pref Shares | - |
| Jan 29, 2018 | Quarterly Results | - |
| Oct 30, 2017 | Quarterly Results | - |
| Aug 02, 2017 | Quarterly Results | - |
| May 04, 2017 | Audited Results | At the ensuring Annual General Meeting, including Notice thereof, for raising funds through issuance of Non-Convertible Debentures on private placement basis. |
| Jan 24, 2017 | Quarterly Results | - |
| Nov 10, 2016 | Quarterly Results & Interim Dividend | - |
| Aug 13, 2016 | Quarterly Results | - |
| May 06, 2016 | Audited Results & Dividend | To consider, issuance of Non-Convertible Debentures on private placement basis. |
| Feb 11, 2016 | Quarterly Results | - |
| Nov 13, 2015 | Quarterly Results | - |
| Aug 10, 2015 | Quarterly Results | - |
| May 28, 2015 | Audited Results & Dividend | - |
| Feb 04, 2015 | Quarterly Results | - |
| Nov 03, 2014 | Quarterly Results & Interim Dividend | - |
| Sep 15, 2014 | Amalgamation | To consider and approve amalgamation of two wholly owned subsidiaries viz Wockhardt Biopharm Limited and Vinton Healthcare Limited with Wockhardt Limited. |
| Aug 12, 2014 | Quarterly Results | - |
| May 26, 2014 | Audited Results & Others | Dividend on Preference Shares |
| Feb 09, 2014 | Quarterly Results & Interim Dividend | - |
| Oct 25, 2013 | Quarterly Results & Interim Dividend | - |
| Aug 14, 2013 | Quarterly Results | - |
| May 27, 2013 | Audited Results & Dividend | - |
| Feb 14, 2013 | Quarterly Results | - |
| Nov 14, 2012 | Quarterly Results | - |
| Aug 06, 2012 | Quarterly Results | - |
| May 22, 2012 | Audited Results & Div. on Pref Shares | To consider the recommendation of Dividend @ 0.01% (Rs. 0.0005 per Preference Share of Rs. 5/- each) on Non-Convertible Cumulative Redeemable Preference Shares of Rs. 5/- each. |
| Feb 13, 2012 | Quarterly Results | - |
| Nov 12, 2011 | Quarterly Results | - |
| Aug 09, 2011 | Quarterly Results & ESOP | - |
| May 19, 2011 | Audited Results | - |
| Feb 02, 2011 | Quarterly Results | - |
| Nov 12, 2010 | Quarterly Results | - |
| Aug 13, 2010 | Quarterly Results & Others | To increase in Authorised Share Capital from Rs. 925 Crs to Rs. 1,125 Crs by creation of 40 Crs Preference Shares of FV of Rs. 5/- each & to issue upto 40 Crs Convertible / NCRPSs of Rs. 5/- each. |
| May 20, 2010 | Audited Results (Fifteen Months) | - |
| Jan 25, 2010 | Quarterly Results | - |
| Nov 18, 2009 | Increase in Authorised Capital & Others | To increase in Authorised Share Capital from Rs. 175 Crs to Rs. 925 Crs by creation of 150 Crs Pref. Shares of Rs. 5/- each & Preferential Issue upto 160 Crs Convertible / NCRPS of Rs. 5/- each. |
| Oct 31, 2009 | Quarterly Results | - |
| Jul 30, 2009 | Quarterly Results & Others | The Board has decided that the Financial Year of the Company ending on December 31, 2009 be extended for a further period of three months to close on March 31, 2010. |
| Apr 24, 2009 | Audited, Quarterly Results & Others | To approve the notice of postal ballot for sale / transfer / disposal of Animal Healthcare Business of the Company to its subsidiary / any other entity / parties. |
| Mar 31, 2009 | Audited Results & Dividend | - |
| Oct 21, 2008 | Quarterly Results | - |
| Jul 28, 2008 | Quarterly Results | - |
| Apr 28, 2008 | Quarterly Results | - |
| Feb 20, 2008 | Audited Results & Final Dividend | - |
| Jan 18, 2008 | Demerger & Raising of funds | In Principle approval of the board to demerge New Chemical Entities (NCE) R&D and certain high value products R&D carried out by the Company. |
| Oct 23, 2007 | Quarterly Results & Interim Dividend | - |
| Jul 25, 2007 | Quarterly Results | - |
| Apr 26, 2007 | Quarterly Results | - |
| Feb 22, 2007 | Accounts, Dividend & Quarterly Results | - |
| Oct 26, 2006 | Quarterly Results | - |
| Jul 27, 2006 | Quarterly Results | - |
| Apr 25, 2006 | Quarterly Results | - |
| Feb 14, 2006 | Accounts, Dividend & Quarterly Results | - |
| Oct 19, 2005 | Quarterly Results | - |
| Jul 19, 2005 | Quarterly Results | - |
| Apr 20, 2005 | Quarterly Results | - |
| Feb 08, 2005 | Dividend & Accounts | - |
| Oct 20, 2004 | Quarterly Results | - |
| Sep 21, 2004 | Others | To consider and approve the issuance of Bonds/GDR's/ADR's/Convertible debentures in domestic/ international market. |
| Jul 26, 2004 | Quarterly Results | - |
| Apr 22, 2004 | Quarterly Results | - |
| Feb 12, 2004 | Accounts, Dividend & Bonus Issue | Sub Division of Equity shares |
| Oct 31, 2003 | Quarterly Results | - |
| Jul 29, 2003 | Quarterly Results & Half Yearly Results | - |
| Apr 30, 2003 | Quarterly Results | - |
| Mar 27, 2003 | Accounts & Dividend | - |
| Oct 29, 2002 | Quarterly Results | - |
| Jul 30, 2002 | Quarterly Results & Half Yearly Results | - |
| Apr 29, 2002 | Quarterly Results | - |
| Mar 08, 2002 | Interim Dividend | (Revised) |
| Feb 12, 2002 | Accounts & Dividend | - |
| Oct 30, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Quarterly Results | - |
| Apr 24, 2001 | Quarterly Results | - |
| Feb 21, 2001 | Accounts & Dividend | - |
| Oct 28, 2000 | Quarterly Results | - |
| Aug 31, 2000 | Quarterly Results | - |
| Apr 11, 2000 | Quarterly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Apr 28, 2004 | 1:2 | - |
05 Jul 2024
WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Change in Management
Pursuant to Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that Mr Prasanna Bharatan has resigned as Internal Auditor of the Company with effect from closing of business hours on Friday, 5th July 2024.
03 Jul 2024
WOCKHARDT LTD. - 532300 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI Listing Regulations, our RTA has intimated about receipt of the requests for issuance of duplicate share certificate(s) in lieu of original share certificate(s) reported lost/misplaced.
02 Jul 2024
Wockhardt enters last mile to bring two of its promising antibiotics to India
Out-licencing talks for overseas markets, after global approvals, says Chairman
02 Jul 2024
WOCKHARDT LTD. - 532300 - Disclosure Of Voting Results Of 25Th Annual General Meeting ('AGM') Pursuant To Regulation 44(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 44(3) of SEBI(LODR) Regulations, 2015, we enclose herewith the combined voting Results of remote e-voting and e-voting during the 25th Annual General Meeting of the Company held on 28th June, 2024 along with the scrutinizer''s report thereon.
01 Jul 2024
Wockhardt stock soars over 19% after its investigational antibiotic Zaynich successfully treats cancer patient in US
This marked the first instance in US, where Zaynich had been used to combat a complex infection caused by extreme-drug-resistant pseudomonas
28 Jun 2024
Wockhardt's novel antibiotic Zaynich to be launched in India by end of FY25
Global launch in FY26 after multinational clinical trial ends
28 Jun 2024
Wockhardt Launches New Antibiotic With $25-Billion Market Potential
The company has invested over $500 million on its research efforts till now.
28 Jun 2024
WOCKHARDT LTD. - 532300 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find enclosed herewith the Scrutinizer''s Report on the voting results of remote e-voting and e-voting during the 25th AGM of the Company held today i.e. 28th June, 2024
28 Jun 2024
WOCKHARDT LTD. - 532300 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
28 Jun 2024
WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Wockhardt Limited has informed regarding the press release dated June 28, 2024 titled "Globally renowned US body Clinical & Laboratory Standard Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime-WCK 5222)".
